|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
|
|
2.
|
Srinivasula SM and Ashwell JD: IAPs:
what's in a name? Mol Cell. 30:123–135. 2008.
|
|
3.
|
Hernandez JM, Farma JM, Coppola D, Hakam
A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D:
Expression of the antiapoptotic protein survivin in colon cancer.
Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Pavlyukov MS, Antipova NV, Balashova MV,
Vinogradova TV, Kopantzev EP and Shakhparonov MI: Survivin monomer
plays an essential role in apoptosis regulation. J Biol Chem.
286:23296–23307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Nowak-Markwitz E, Puła B, Szajnik M,
Dziegiel P, Piotrowska A, Zabel M and Spaczyński M: Expression of
survivin, SDF-1 and CXCR on tumor cells in ovarian cancer. Ginekol
Pol. 81:674–677. 2010.PubMed/NCBI
|
|
6.
|
Kim K, Chie EK, Wu HG, Kim SG, Lee SH,
Kang GH, Hyun CL and Ha SW: High survivin expression as a predictor
of poor response to preoperative chemoradiotherapy in locally
advanced rectal cancer. Int J Colorectal Dis. 26:1019–1023. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Adamkov M, Halasova E, Kajo K, Machalekova
K, Vybohova D, Varga I and Rajcany J: Survivin: a promising
biomarker in breast carcinoma. Neoplasma. 57:572–577. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hoffman WH, Biade S, Zilfou JT, Chen J and
Murphy M: Transcriptional repression of the anti-apoptotic survivin
gene by wild type p53. J Biol Chem. 277:3247–3257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Mirza A, McGuirk M, Hockenberry TN, Wu Q,
Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen
LL, Pickett CB and Liu S: Human survivin is negatively regulated by
wild-type p53 and participates in p53-dependent apoptotic pathway.
Oncogene. 21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lee CW, Raskett CM, Prudovsky I and
Altieri DC: Molecular dependence of estrogen receptor-negative
breast cancer on a notch-survivin signaling axis. Cancer Res.
68:5273–5281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Vaira V, Lee CW, Goel HL, Bosari S,
Languino LR and Altieri DC: Regulation of survivin expression by
IGF-1/mTOR signaling. Oncogene. 26:2678–2684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Li F: Survivin study: what is the next
wave? J Cell Physiol. 197:8–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Altieri DC, Marchisio PC and Marchisio C:
Survivin apoptosis: an interloper between cell death and cell
proliferation in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
|
|
14.
|
Shu MG, Guo XT, Zhen HN, Han Y, Chen FL,
Li LW and Guo SZ: Enhancing skin flap survival by a cell-permeable
wild-type survivin. Med Hypotheses. 69:888–891. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu
M, Xu N and Xiao Z: High expression of survivin predicts poor
prognosis in esophageal squamous cell carcinoma following
radiotherapy. Tumour Biol. 32:1147–1153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Trabulo S, Cardoso AM, Santos-Ferreira T,
Cardoso AL, Simões S and Pedroso de Lima MC: Survivin silencing as
a promising strategy to enhance the sensitivity of cancer cells to
chemotherapeutic agents. Mol Pharm. 8:1120–1131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Park E, Gang EJ, Hsieh YT, Schaefer P,
Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H,
Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J,
Kahn M, Müschen M and Kim YM: Targeting survivin overcomes drug
resistance in acute lymphoblastic leukemia. Blood. 118:2191–2199.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Takizawa BT, Uchio EM, Cohen JJ, Wheeler
MA and Weiss RM: Downregulation of survivin is associated with
reductions in TNF receptors' mRNA and protein and alterations in
nuclear factor kappa B signaling in urothelial cancer cells. Cancer
Invest. 25:678–684. 2007.PubMed/NCBI
|
|
19.
|
Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y
and Feng Y: Inhibition of survivin reduces cell proliferation and
induces apoptosis in human endometrial cancer. Cancer. 107:746–756.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Malcles MH, Wang HW, Koumi A, Tsai YH, Yu
M, Godfrey A and Boshoff C: Characterisation of the anti-apoptotic
function of survivin-DeltaEx3 during TNF alpha-mediated cell death.
Br J Cancer. 96:1659–1666. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Nassar A, Lawson D, Cotsonis G and Cohen
C: Survivin and caspase-3 expression in breast cancer: correlation
with prognostic parameters, proliferation, angiogenesis, and
outcome. Appl Immunohistochem Mol Morphol. 16:113–120. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Giatromanolaki A, Sivridis E and
Koukourakis MI: Angiogenesis in colorectal cancer: prognostic and
therapeutic implications. Am J Clin Oncol. 29:408–417. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kleespies A: Vascular endothelial growth
factor in esophageal cancer. J Surg Oncol. 87:95–104. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Yasumitsu A, Tabata C, Tabata R and
Hirayama N: Clinical significance of serum vascular endothelial
growth factor in malignant pleural mesothelioma. J Thorac Oncol.
5:479–483. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Zhu H, Chen XP, Zhang WG, Luo SF and Zhang
BX: Expression and significance of new inhibitor of apoptosis
protein survivin in hepatocellular carcinoma. World J
Gastroenterol. 11:3855–3859. 2005.PubMed/NCBI
|
|
27.
|
Zhang HY, Meng X, Du ZX, et al:
Significance of survivin, caspase-3, and VEGF expression in thyroid
carcinoma. Clin Exp Med. 9:207–213. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Ryan BM, Konecny GE, Kahlert S, Wang HJ,
Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ and
Duffy MJ: Survivin expression in breast cancer predicts clinical
outcome and is associated with HER2, VEGF, urokinase plasminogen
activator and PAI-1. Ann Oncol. 17:597–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Beierle EA, Nagaram A, Dai W, Iyengar M
and Chen MK: VEGF-mediated survivin expression in neuroblastoma
cells. J Surg Res. 127:21–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Nakahara T, Yamanaka K, Hatakeyama S, Kita
A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T,
Koutoku H and Sasamata M: YM155, a novel survivin suppressant,
enhances taxane-induced apoptosis and tumor regression in a human
Calu 6 lung cancer xenograft model. Anticancer Drugs. 22:454–462.
2011. View Article : Google Scholar : PubMed/NCBI
|
